Live Breaking News & Updates on பிரஞ்சு சந்தை அதிகாரம்

Stay updated with breaking news from பிரஞ்சு சந்தை அதிகாரம். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Strengthening of Pherecydes Pharma's Patent Portfolio with Two New Patents Granted in the United States


(2)
Regulatory News:
Pherecydes Pharma (Paris:ALPHE) (FR0011651694 ALPHE), a biotechnology company specializing in precision phage therapy for the treatment of resistant and/or complicated bacterial infections, today announced that the United States Patent and Trademark Office (USPTO) has granted two patents for its
anti-Pseudomonas Aeruginosa and
Guy-Charles Fanneau de La Horie, CEO of Pherecydes Pharma, says:
We are very pleased that the USPTO has granted us these two new patents for our anti-Pseudomonas aeruginosa and anti-E. Coli phages. These two new patents in the world s leading healthcare market greatly expand the geographical areas in which our phages are now protected. This is a further evidence of the relevance of the intellectual property strategy we have implemented. We will continue to protect our champion phages with this now proven strategy. ....

United States , Hong Kong , United Kingdom , Pherecydes Pharma , Philippe Rousseau , Nicolas Merigeau , Dusan Oresansky , Prospectus Directive Of The European Union , Trademark Office , Regulations Of The French Market Authority Autorit , European Parliament , Financial Services , Regulatory News , United States Patent , Pseudomonas Aeruginosa , Charles Fanneau De La Horie , French National Agency , French Monetary , Financial Code , General Regulations , French Market Authority , Des March , Prospectus Directive , European Union , Markets Act , Financial Promotion ,

Resounding Success of Pherecydes Pharma's IPO on the Euronext Growth Market in Paris


Resounding Success of Pherecydes Pharma s IPO on the Euronext Growth Market in Paris
Offer oversubscribed 4 times, with global demand totaling €28.1 million
Capital increase of approximately €8 million, after full exercise of the Extension Clause
Trading in the Company s shares begins on February 5, 2021 (FR0011651694 ALPHE)
Regulatory News:
Pherecydes Pharma (Paris:ALPHE) (FR0011651694 ALPHE), a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, today announces the resounding success of its initial public offering on the Euronext Growth
market in Paris.
Guy-Charles Fanneau de La Horie, Chairman of the Executive Board of Pherecydes Pharma, says:
I am particularly sensitive to the high level of interest the financial community has shown in our IPO project, both institutional and individual investors. I would like to thank all our shareholders, longstanding and new, who h ....

United States , France General , United Kingdom , Pherecydes Pharma , Philippe Rousseau , Bpifrance Entreprise , Kostenloser Wertpapierhandel , Nicolas Merigeau , Dusan Oresansky , Entreprise Innovante , Regulations Of The French Market Authority Autorit , European Parliament , Early Access Program , Financial Services , Company Supervisory Board , Prospectus Directive Of The European Union , Document May Not Be Published , Either Directly , Charles Fanneau De La Horie , Executive Board , Global Placement , Extension Clause , Escherichia Coli , Fixed Price Offer , Euronext Growth , Supervisory Board ,

GROUPE SEB: Biannual Report on SEB S.A.'S Liquidity Agreement Entrusted to NATIXIS ODDO BHF


GROUPE SEB: Biannual Report on SEB S.A. S Liquidity Agreement Entrusted to NATIXIS ODDO BHF - 31st December 2020
GROUPE SEB (Paris:SK):
An addendum to the liquidity agreement has been executed on 20 December 2019 with NATIXIS ODDO BHF in accordance with the Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse, the Commission Delegated Regulation (EU) 2016/908 of 26 February 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and the AMF (French Market Authority) decision N° 2018- 01 of 2 July 2018 setting up the liquidity agreements for capital securities as normal market practice.
Under the liquidity agreement entrusted by SEB SA (Paris: SK) to NATIXIS ODDO BHF, the following assets appeared on the dedicated liquidity account at ....

France General , Moulin Carron , Shareholders Departmenti Campus , European Parliament , Commission Delegated Regulation , French Market Authority , Regulatory News , பிரான்ஸ் ஜநரல் , மவுலின் கரோன் , ஐரோப்பிய பாராளுமன்றம் , பிரஞ்சு சந்தை அதிகாரம் , ஒழுங்குமுறை செய்தி ,